QuantumPharm, Inc. (HK:2228)
:2228
Want to see HK:2228 full AI Analyst Report?
Top Page
QuantumPharm, Inc.
(2228)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$9.00
▼(-13.88% Downside)
Action:Reiterated
Date:04/25/26
The score is held down primarily by persistent operating losses and ongoing cash burn, despite strong recent revenue/gross profit growth and a materially improved balance sheet. Technicals are bearish with the stock trading below major moving averages, and valuation is a further headwind given the very high P/E and no dividend yield provided.
Positive Factors
Rapid revenue & gross profit growth
Sharp top-line and gross profit expansion in 2025 demonstrates strong market traction and improving unit economics. Sustained revenue growth at scale can enable operating leverage, support reinvestment in product and sales, and materially improve long-term margin sustainability if cost structure tightens.
Negative Factors
Persistent negative operating and free cash flow
Consistent negative operating and free cash flow means the company still burns cash despite revenue growth, creating an ongoing need for external financing. Over months this raises refinancing and dilution risk, limiting the firm's ability to self-fund capex or strategic initiatives without raising capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid revenue & gross profit growth
Sharp top-line and gross profit expansion in 2025 demonstrates strong market traction and improving unit economics. Sustained revenue growth at scale can enable operating leverage, support reinvestment in product and sales, and materially improve long-term margin sustainability if cost structure tightens.
Read all positive factors
QuantumPharm, Inc. (2228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$32.91B
Dividend YieldN/A
Average Volume (3M)143.30M
Price to Earnings (P/E)226.5
Beta (1Y)0.94
Revenue Growth200.45%
EPS GrowthN/A
CountryHK
Employees809
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,303,371,600
10 Day Avg. Volume160,836,692
30 Day Avg. Volume143,301,077
Financial Highlights & Ratios
PEG Ratio-2.56
Price to Book (P/B)3.42
Price to Sales (P/S)41.11
P/FCF Ratio-160.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.21Price Target Upside26.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$993.31M
QuantumPharm, Inc. Business Overview & Revenue Model
Company Description
XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery...
QuantumPharm, Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 781.85M | 266.43M | 174.42M | 133.35M | 62.80M |
| Gross Profit | 544.71M | 123.43M | 48.24M | 66.09M | 32.78M |
| EBITDA | -383.89M | -631.38M | -1.78B | -1.38B | -2.11B |
| Net Income | 120.54M | -1.52B | -1.91B | -1.44B | -2.14B |
Balance Sheet | |||||
| Total Assets | 10.22B | 4.35B | 4.01B | 4.32B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 7.07B | 3.10B | 2.83B | 3.47B | 3.83B |
| Total Debt | 443.46M | 148.76M | 11.04B | 9.45B | 7.83B |
| Total Liabilities | 786.95M | 362.43M | 11.25B | 9.63B | 7.99B |
| Stockholders Equity | 9.39B | 3.96B | -7.27B | -5.33B | -3.61B |
Cash Flow | |||||
| Free Cash Flow | -199.96M | -536.79M | -698.20M | -627.83M | -417.42M |
| Operating Cash Flow | -139.62M | -478.68M | -567.56M | -429.10M | -253.75M |
| Investing Cash Flow | -3.87B | 74.09M | 735.58M | -2.76B | -70.47M |
| Financing Cash Flow | 5.43B | 840.00M | -25.89M | 57.99M | 2.48B |
QuantumPharm, Inc. Technical Analysis
Negative
10.45
Price Trends
8.95
Negative
10.11
Negative
10.35
Negative
Market Momentum
-0.38
Positive
34.90
Neutral
11.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Negative. The current price of 10.45 is above the 20-day moving average (MA) of 8.26, above the 50-day MA of 8.95, and above the 200-day MA of 10.35, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 34.90 is Neutral, neither overbought nor oversold. The STOCH value of 11.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2228.
QuantumPharm, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$63.66B | 39.04 | 16.29% | ― | 46.83% | 36.46% | |
60 Neutral | HK$3.54B | -26.53 | -32.00% | ― | 410.53% | ― | |
56 Neutral | HK$1.07B | -14.29 | -3.55% | ― | -16.30% | -113.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | HK$1.57B | -10.72 | -39.41% | ― | ― | 39.48% | |
46 Neutral | HK$14.95B | -117.79 | -2.97% | ― | 30.48% | 65.41% | |
42 Neutral | HK$32.91B | 226.48 | 1.50% | ― | 200.45% | ― |
* General Sector Average
HK:2228
QuantumPharm, Inc.
7.49
2.74
57.68%
HK:2268
WuXi XDC Cayman, Inc.
50.15
8.45
20.26%
HK:2502
Henan Jinyuan Hydrogenated Chemicals Co., Ltd. Class H
0.59
0.24
68.57%
HK:2511
Hightide Therapeutics Inc
2.99
0.38
14.56%
HK:2498
RoboSense Technology Company., Ltd
32.22
-0.38
-1.17%
HK:2509
Qyuns Therapeutics Co., Ltd. Class H
15.23
0.43
2.91%
QuantumPharm, Inc. Corporate Events
XtalPi’s QuantumPharm Commits RMB356 Million to Low-Risk SPDB Structured Deposits
May 5, 2026
XtalPi Holdings Limited’s subsidiary QuantumPharm Limited has subscribed to a new batch of exchange-rate linked, principal‑guaranteed structured deposits issued by Shanghai Pudong Development Bank, committing RMB356.1 million on 11 Sep...
XtalPi Plans New Share Scheme and Governance Overhaul Ahead of AGM
Apr 17, 2026
XtalPi Holdings Limited will seek shareholder approval at its upcoming annual general meeting to adopt a new share scheme aimed at better aligning directors and employees with the company’s long-term interests. The scheme is designed to stre...
XtalPi Sets 2026 AGM to Seek Shareholder Mandates on Buy-backs and New Issues
Apr 17, 2026
XtalPi Holdings Limited has called its annual general meeting for 20 May 2026 in Shenzhen, where shareholders will review the audited consolidated financial statements for the year ended 31 December 2025 and receive reports from the board and the ...
XtalPi Grants Over 22 Million Equity Awards to Employees to Boost Incentives
Apr 9, 2026
XtalPi Holdings Limited has granted 11,234,290 share options to 137 employees and 10,920,770 restricted share units to 270 employees under its existing equity incentive schemes, with all awards subject to acceptance. The move, which excludes direc...
XtalPi Swings to Profit on Surging 2025 Revenue and Heavy R&D Spend
Mar 25, 2026
XtalPi Holdings Limited reported a sharp increase in revenue to RMB802.6 million for the year ended 31 December 2025, up from RMB266.4 million a year earlier, reflecting strong business expansion. The company remained RD-intensive, with research a...
XtalPi Sets March 25 Board Meeting to Approve 2025 Annual Results
Mar 13, 2026
XtalPi Holdings Limited has scheduled a board meeting for 25 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025 and to authorize their publication. The board will also consider the payme...
XtalPi Names Veteran Healthcare Banker Zhou Feiran as Chief Financial Officer
Mar 10, 2026
XtalPi Holdings Limited has appointed Zhou Feiran as its new chief financial officer, effective 10 March 2026, strengthening its senior leadership team with a seasoned capital markets specialist. Zhou brings over 12 years of experience in global h...
XtalPi Signals First Full-Year Profit on Revenue Surge and Valuation Gains
Mar 3, 2026
XtalPi Holdings has issued a positive profit alert, signaling a turnaround from a net loss of about RMB1.5 billion in 2024 to an expected net profit of at least RMB100 million in 2025, marking its first full-year profit. The shift is driven by a p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.